Android app on Google Play

OXIGENE (OXGN) Rips After Geting SPA From FDA for ZYBRESTAT Phase 3

September 17, 2012 4:35 PM EDT Send to a Friend
Get Alerts OXGN Hot Sheet
Trade OXGN Now!
Join SI Premium – FREE
OXIGENE (Nasdaq: OXGN) shares are popping higher in late trading Monday after announcing it came to a Special Protocol Assessment (SPA) with the FDA for its Phase 3 clinical trial (FACT 2) of ZYBRESTAT for the treatment of anaplastic thyroid cancer (ATC).

Shares are up over 18 percent.




You May Also Be Interested In


Related Categories

FDA, Momentum Movers

Add Your Comment